Literature DB >> 9734398

Differentiation and reversal of malignant changes in colon cancer through PPARgamma.

P Sarraf1, E Mueller, D Jones, F J King, D J DeAngelo, J B Partridge, S A Holden, L B Chen, S Singer, C Fletcher, B M Spiegelman.   

Abstract

PPARgamma is a nuclear receptor that has a dominant regulatory role in differentiation of cells of the adipose lineage, and has recently been shown to be expressed in the colon. We show here that PPARgamma is expressed at high levels in both well- and poorly-differentiated adenocarcinomas, in normal colonic mucosa and in human colon cancer cell lines. Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer. Transplantable tumors derived from human colon cancer cells show a significant reduction of growth when mice are treated with troglitazone, a PPARgamma ligand. These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPARgamma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9734398     DOI: 10.1038/2030

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  268 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms.

Authors:  Daniel H Hwang; Victor Fung; Andrew J Dannenberg
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

3.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.

Authors:  Y F Guan; Y H Zhang; R M Breyer; L Davis; M D Breyer
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 4.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

5.  Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.

Authors:  Vladimir Petrovic; Robert H Costa; Lester F Lau; Pradip Raychaudhuri; Angela L Tyner
Journal:  Cancer Biol Ther       Date:  2010-06-06       Impact factor: 4.742

6.  Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.

Authors:  Chuanbing Zang; Marlies Wächter; Hongyu Liu; Maximilian G Posch; Martin H Fenner; Christine Stadelmann; Andreas von Deimling; Kurt Possinger; Keith L Black; H Phillip Koeffler; Elena Elstner
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

Review 7.  Development of Preclinical Models to Understand and Treat Colorectal Cancer.

Authors:  Judith S Sebolt-Leopold
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

8.  Peroxisome proliferator-activated receptor-γ agonist-mediated inhibition of cell growth is independent of apoptosis in human epidermoid carcinoma A431 cells.

Authors:  Qian Li; Yu-Sheng Peng; Ping-Jiao Chen; Meng-Lei Wang; Can Cao; Hao Xiong; Jing Zhang; Ming-Hua Chen; Xue-Biao Peng; Kang Zeng
Journal:  Oncol Lett       Date:  2018-02-28       Impact factor: 2.967

9.  Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis.

Authors:  Evan D Rosen; Rohit N Kulkarni; Pasha Sarraf; Umut Ozcan; Terumasa Okada; Chung-Hsin Hsu; Daniel Eisenman; Mark A Magnuson; Frank J Gonzalez; C Ronald Kahn; Bruce M Spiegelman
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

10.  Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk.

Authors:  Hansong Wang; Darin Taverna; Daniel O Stram; Barbara K Fortini; Iona Cheng; Lynne R Wilkens; Terrilea Burnett; Karen W Makar; Noralane M Lindor; John L Hopper; Steve Gallinger; John A Baron; Robert Haile; Laurence N Kolonel; Brian E Henderson; Polly A Newcomb; Graham Casey; David Duggan; Cornelia M Ulrich; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.